Investor Relations

About Certara

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies.

View company overview

News releases

View all
Nov 05, 2026

Certara delivers a solid quarter with double-digit software revenue growth Updates 2026 financial outlook Appoints Grant Peterson Chief Product Officer Company to host conference call and webcast today at 8:30 a.m. ET  RADNOR, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.

Read more
Oct 26, 2026

RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 before market open on Thursday, November 5th, 2026.

Read more
Aug 04, 2026

A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.

Read more